Clinical Trials Arena on MSN
Milestone’s etripamil nasal spray enters phase III trial for atrial fibrillation
The primary goal of the ReVeRA-301 study is to achieve a reduction in ventricular rate within 30 minutes.
Shares of Milestone Therapeutics MIST fell 21.67% during market hours on Oct 17, after rising 41% in premarket, post the company’s announcement of top-line results from a late-stage study evaluating ...
Milestone Pharmaceuticals Inc (NASDAQ:MIST) shares gained 3.9% on Friday after the company announced that the first patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results